RESEARCH REPORT
Thermo Fisher Scientific Inc
TMO
$697.00
As of 2026-11-01
Research note — 2026-11-01. Educational analysis, not financial advice.
The one-line version
Thermo Fisher Scientific Inc trades near $697.00 on a trailing multiple of about 36.8x versus its own 5-year median near 30.5x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.
That's the tension. Everything below is the detail.
1. What you're paying
| Now | Its own 5-year median | Gap | |
|---|---|---|---|
| P/E (trailing) | ~36.8 | ~30.5 | +21% |
| P/E (forward) | ~25.1 | — | — |
| EPS (TTM) | 18.96 | — | — |
| Gross margin | 41.2% | — | — |
What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.
Fair-value anchors on file:
- 5-year median P/E multiple: $577.86 — Applies the 5-year median multiple (30.5x) to trailing EPS.
- Street mean target: $752.12 — Average published analyst target.
- Street target midpoint: $710.00 — Midpoint of $590.00–$830.00 published range.
Street targets run from $590.00 to $830.00. A wide spread means the name is contested, not consensus.
2. What the bulls are counting on
- Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q3 Beat And Higher Guidance
- Benzinga's 'Stock Whisper' Index: Five Stocks market participants Secretly Monitor But Don't Talk About Yet
- How market participants Are Reacting To Thermo Fisher Scientific Stock After Strong Q3 Earnings
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
3. What the bears see
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGEN
- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AI
- Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
4. What would have to be true
For the stock to justify ~36.8x rather than its 5-year ~30.5x, roughly all of the following need to neutral:
- Growth or margin durability shows up in the next several reports, not just in narrative.
- Key revenue concentrations survive competitive and regulatory pressure.
- Execution on the current product or services cycle stays on schedule.
- The Street target range compresses as results clarify the contested assumptions.
Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
5. What to watch next
- Next earnings date: 2027-01-27
- Trailing and forward multiples versus the company's own history
- Segment growth rates in the next 10-Q / earnings release
- Material Form 4 and 13F changes
- Whether the Street high-to-low target spread narrows or widens
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
6. What this note does not do
It doesn't tell you to buy or sell. It won't, ever.
You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.
If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.
Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-01 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.
8. Analyst ratings & targets
No recent activity
Analyst opinions change frequently. Past upgrades do not predict future returns.
9. Important news
Nov 7, 2026|How IDEXX Stock Is Engineered To Make Money For You(Yahoo)
For questions about this article or underlying research, email help@trefis.com.
Nov 6, 2026|Global Oligonucleotide Synthesis Services Market Report 2026 | Capitalize on $4.7B by 2030 as Thermo Fisher, Agilent, QIAGEN and IDT Accelerate GMP and CRISPR Capacity(Yahoo)
Boost ROI via low-scale custom oligos, reduced waste, rapid turnaround, seamless scaling, regional sourcing, and distribution partnerships.Dublin, Nov. 06, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Synthesis Services Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global oligonucleotide synthesis services market is experiencing strong growth as demand increases across genomics, molecular diagnostics, gene editing and nucleic acid therapeutics. The market expanded fro
Nov 6, 2026|Capital Group Growth (CGGR) Buys $16.8 Million More Seagate on Nov. 4(Yahoo)
The ETF bought $16.8 million of Seagate and $10.4 million of Meta while selling $119.5 million of Apple on Wednesday.
Nov 6, 2026|Diamond Hill Large Cap Fund Q3 2026 Portfolio Update(SeekingAlpha)
Diamond Hill Large Cap Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Read more here.
Nov 6, 2026|Are eBay & Deere stocks under-the-radar AI beneficiaries?(Yahoo)
Gus Scacco, senior portfolio manager at Advisors Capital, looks beyond AI infrastructure to focus on companies using the technology to improve productivity, cash flow, and profitability.
News headlines are reported as-is. Verify important claims with original sources.
10. Insider Form 4 activity
| Date | Executive | Action | Shares | Value |
|---|---|---|---|---|
| Oct 28, 2026 | SPERLING SCOTT M | Sell | 3,490 | $0 |
| Oct 28, 2026 | Britt Lisa P. (Sr. VP and Chief HR Officer) | Sell | 2,831 | $2.0M |
Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.
11. Institutional 13F holdings
| Fund | Shares | Position | Change |
|---|---|---|---|
| Vanguard Group | 30,425,604 | $17.6B | — |
| State Street | 16,825,879 | $8.4B | — |
| BlackRock | 8,666,318 | $4.8B | — |
| BlackRock Institutional Trust | 616,250 | $87.0M | — |
These are 45-day lagged filings (SEC requirement). Position changes happened in the past.
12. Earnings this week
No recent activity
Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.